On Nov 13, major Wall Street analysts update their ratings for $RAPT Therapeutics (RAPT.US)$, with price targets ranging from $2 to $4.
Wells Fargo analyst Yanan Zhu maintains with a buy rating, and maintains the target price at $4.
Stifel analyst Alex Thompson CFA downgrades to a hold rating, and sets the target price at $2.
H.C. Wainwright analyst Ram Selvaraju maintains with a hold rating.
Leerink Partners analyst Thomas Smith maintains with a hold rating, and adjusts the target price from $10 to $2.
Furthermore, according to the comprehensive report, the opinions of $RAPT Therapeutics (RAPT.US)$'s main analysts recently are as follows:
Rapt Therapeutics experienced a downgrade in its rating following the termination of the zelnecirnon program. The decision to discontinue the program was based on feedback from the FDA, which implied challenges in disproving the potential for drug-induced liver failure. With the absence of detailed data and the anticipation of a capital raise to support the development of new compounds, the company's prospects are now considered to be contingent upon demonstrating more clarity in its future direction.
The FDA's cautious approach, requiring definitive evidence concerning liver SAE, was contrary to expert predictions. There was, however, a positive indication of efficacy from the Phase 2b trials, which suggests promising prospects for the next-generation compound. The market is looking forward to data that will help in evaluating its potential.
Here are the latest investment ratings and price targets for $RAPT Therapeutics (RAPT.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月13日，多家華爾街大行更新了$RAPT Therapeutics (RAPT.US)$的評級，目標價介於2美元至4美元。
富國集團分析師Yanan Zhu維持買入評級，維持目標價4美元。
斯迪富分析師Alex Thompson CFA下調至持有評級，目標價2美元。
H.C. Wainwright分析師Ram Selvaraju維持持有評級。
Leerink Partners分析師Thomas Smith維持持有評級，並將目標價從10美元下調至2美元。
此外，綜合報道，$RAPT Therapeutics (RAPT.US)$近期主要分析師觀點如下：
rapt therapeutics在zelnecirnon項目終止後，其評級遭到下調。終止該項目的決定是基於FDA的反饋，暗示在駁斥藥物引起的肝衰竭的潛在風險方面存在挑戰。在缺乏詳細數據的情況下，以及預計將進行資本籌集以支持新compound的開發，公司前景現在被認爲依賴於在未來方向上展示更多明確性。
FDA的謹慎態度要求提供關於肝臟不良事件的確定證據，這與專家的預測相反。然而，來自20億臨床試驗的積極效能跡象，表明下一代compound有良好的前景。市場期待能夠幫助評估其潛力的數據。
以下爲今日4位分析師對$RAPT Therapeutics (RAPT.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
